TY - JOUR T1 - Haplotype of <em>RNASE 3</em> polymorphisms is associated with severe malaria in an Indian population JF - medRxiv DO - 10.1101/2020.06.16.20133090 SP - 2020.06.16.20133090 AU - Benudhar Mukhi AU - Himanshu Gupta AU - Samuel C. Wassmer AU - Anupkumar R. Anvikar AU - Susanta Kumar Ghosh Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/18/2020.06.16.20133090.abstract N2 - Severe malaria (SM) caused by Plasmodium falciparum (Pf) infection has been associated with life-threatening anemia, metabolic acidosis, cerebral malaria and multiorgan dysfunction. It may lead to death if not treated promptly. RNASE 3 has been linked to Pf growth inhibition and its polymorphisms found associated with SM and cerebral malaria in African populations. This study aimed to assess the association of RNASE 3 polymorphisms with SM in an Indian population. RNASE 3 gene and flanking regions were amplified followed by direct DNA sequencing in 151 Indian patients who visited Wenlock District Government Hospital, Mangalore, Karnataka, India. Allele, genotype and haplotype frequencies were compared between patients with SM (n=47) and uncomplicated malaria (UM; n=104). Homozygous mutant genotype was only found for rs2233860 polymorphism (&lt;1% frequency). No significant genetic associations were found for RNASE 3 polymorphism genotypes and alleles in Indian SM patients. C-G-G haplotype of rs2233859, rs2073342 and rs2233860 polymorphisms was correlated significantly with SM patients (OR=3.03; p&lt;0.001). Overall, these results suggest that RNASE 3 gene plays a role in susceptibility to severe malaria.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe also acknowledge Indian Council of Medical Research, New Delhi, for funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research and ethics committee of the Kasturba Medical College (KMC) under Manipal Academy of Higher Education, Mangalore, Karnataka, India, approved the study (IEC KMC MLR 03-16/49). The Institutional review board of ICMR-National Institute of Malaria Research, New Delhi, India also reviewed and approved the study (ECR/NIMR/EC/2012/39).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data is available on request ER -